【Important】Response to the spread of the new coronavirus
The spread of the new coronavirus continues to cause turmoil around the world.
We understand that many of you reading this site are also going about your daily lives in a state of anxiety.
While obtaining the latest information from reliable news sources, it is important not to panic more than necessary, but to work together with your neighbors and act calmly.
In consideration of the safety of patients, medical institutions, staff, and donors, we, Japanbiome, have decided to take the following measures.
∙ In accordance with the government policy of minimizing outings, one person involved in dispatch operations, etc., and a maximum of two persons will be on duty for a short period of time, while other staff members will work from home in principle.
∙ After today (March 30), the acceptance of new donor flights will be suspended indefinitely.
All donor stools received after January 16, when the first infection was confirmed in Japan, will not be accepted for use as transplantation fluid.
This decision may make it more difficult for us to provide some of our services, such as simplified responses to inquiries.
For patients currently undergoing transplantation
The intestinal flora transplants that we currently offer to our patients use only intestinal bacteria provided by donors prior to January 15, 2020.
This is before January 16, 2020, when the first case of novel coronavirus infection was confirmed in Japan (a Chinese man in Kanagawa Prefecture), and we believe it is safe to do so.
Please be assured that for the time being, both donor stools and the Ultra Fine Bubble water used to treat the stools have materials that were in stock prior to the spread of the infection.
For those considering testing or transplantation
Intestinal flora balance tests can be accepted as usual as of March 30, 2020.
Please apply to each affiliated medical institution.
As of March 30, 2020, intestinal flora transplants can be accepted and shipped as usual.
For donor stools donated before the infection was confirmed in Japan, we have enough stock for transplants for the time being.
However, if the current situation persists for a prolonged period of time, we may run out of stock of some donors, and we may be forced to temporarily stop accepting new transplant patients in the future.
Contact us
We sincerely hope that the situation will be brought under control as soon as possible, and the institute will take all possible measures to ensure “safety first.
If you have any questions, please use the inquiry form on this website or contact our affiliated medical institutions.
その他の Notices and Activity Reports に関する記事
Articles about other Notices and Activity Reports

November 16, 2026
10th Scientific Conference of the Association for Clinical Research of Fecal Microbiota Transplantation Japan [Event Report]
The Association for Clinical Research of Fecal Microbiota Transplantation Japan (General Incorporated Foundation) held its 10th Scientific Conference on Sunday, 27 September 2026. At this milestone 10th conference, we presented the latest findings and clinical data on “NanoGAS®-FMT” across a wide range of clinical fields, including cancer, gastroenterology, neurodevelopmental disorders and endoscopic examinations, for those […]

October 06, 2026
Survey Summary from the 10th Annual Academic Conference
The 10th Annual Academic Conference was held on September 27, 2026.The event was conducted in a hybrid format, both on-site and online, with close to 150 participants in total, including healthcare professionals, corporate representatives, research institution staff, and even patients, their families, and members of the general public. In this article, we share the results […]

October 28, 2024
〈Clinical Trial〉Completion Report
We are pleased to report the completion of the specified clinical trial titled “Specified Clinical Trial on the Efficacy and Safety of a Novel Fecal Microbiota Transplantation Method for Autism Spectrum Disorder,” which was initiated by our research group in May 2023. This specified clinical trial is published on the jRCT (Japan Registry of Clinical […]